Improving the Dutch Newborn Screening for Central Congenital Hypothyroidism by Using 95% Reference Intervals for Thyroxine-Binding Globulin

Kevin Stroek\textsuperscript{a} Annemieke C. Heijboer\textsuperscript{a,b} Marja van Veen-Sijne\textsuperscript{a}
Annet M. Bosch\textsuperscript{c} Catharina P.B. van der Ploeg\textsuperscript{d} Nitash Zwaveling-Soonawala\textsuperscript{e}
Robert de Jonge\textsuperscript{f} A.S. Paul van Trotsenburg\textsuperscript{e} Anita Boelen\textsuperscript{a}

\textsuperscript{a}Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; \textsuperscript{b}Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands; \textsuperscript{c}Division of Metabolic Disorders, Department of Pediatrics, Emma Children’s Hospital, Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; \textsuperscript{d}Department of Child Health, Netherlands Organization for Applied Scientific Research TNO, Leiden, The Netherlands; \textsuperscript{e}Department of Paediatric Endocrinology, Emma Children’s Hospital, Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; \textsuperscript{f}Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit & University of Amsterdam, Amsterdam, The Netherlands

Keywords
Newborn screening · Central congenital hypothyroidism · Reference intervals · Thyroxine · Thyroxine-binding globulin

Abstract

\textbf{Introduction}: Newborn screening (NBS) for congenital hypothyroidism (CH) in the Netherlands consists of thyroxine (T\textsubscript{4}), thyroid-stimulating hormone (TSH), and T\textsubscript{4}-binding globulin (TBG) measurements to detect thyroidal CH and central CH (CH-C). CH-C is detected by T\textsubscript{4} or a calculated T\textsubscript{4}/TBG ratio, which serves as an indirect measure of free T\textsubscript{4}. TSH and TBG are only measured in the lowest 20 and 5% of daily T\textsubscript{4} values, respectively. A recent evaluation of the Dutch NBS for CH showed that the T\textsubscript{4} and T\textsubscript{4}/TBG ratio contribute to the detection of CH-C but also lead to a low positive predictive value (PPV). Dried blood spot (DBS) reference intervals (RIs) are currently unknown and may contribute to improvement of our NBS algorithm. \textbf{Materials and Methods}: RIs of T\textsubscript{4}, TSH, TBG, and the T\textsubscript{4}/TBG ratio were determined according to Clinical & Laboratory Standards Institute guidelines in heel puncture cards from routine NBS in both sexes and at the common NBS sampling ages. Scatter plots were used to compare the healthy reference population to previously published data of CH-C patients and false positives. \textbf{Results}: Analyses of 1,670 heel puncture cards showed small differences between subgroups and led to the formulation of total sample DBS RIs for T\textsubscript{4} (56–118 nmol/L), TSH (<2.6 mIU/L), TBG (116–271 nmol/L), and the T\textsubscript{4}/TBG ratio (>20). 46% of false-positive referrals based on T\textsubscript{4} alone had a TBG below

A.S. Paul van Trotsenburg and Anita Boelen shared last authorship.
Improving the Dutch Newborn Screening for Central Congenital Hypothyroidism

Introduction

Congenital hypothyroidism (CH) is thyroid hormone deficiency at birth mostly caused by impaired development of the thyroid gland or hormone biosynthesis (primary or thyroidal CH, CH-T). A less frequent, but equally important cause is hypothalamic or pituitary dysfunction, named secondary or central CH (CH-C) [1]. Early detection and treatment of CH prevent neurodevelopmental disabilities. Therefore, CH has been included in many newborn screening (NBS) programs worldwide since the 1970s [2]. Most programs employ a thyroid-stimulating hormone (TSH)-based strategy aiming at detection of CH-T [3]. However, newborns with CH-C – who typically have a low T4 in combination with a normal TSH concentration – will be missed [2]. In the Netherlands, the NBS strategy for CH is primarily based on the measurement of dried blood spot (DBS) T4 in order to screen for both CH-T and CH-C. Unique for the Dutch approach is that to detect CH-T, TSH is measured in the lowest 20% of T4 concentrations, and in order to detect CH-C, thyroxine-binding globulin (TBG) is measured in the lowest 5% of T4 concentrations enabling calculation of a modified T4/TBG ratio that serves as an indirect measure of free T4 (FT4). With this approach, low T4 values due to TBG deficiency can be excluded, and only neonates at risk for CH-C, that is, those with a low T4 value combined with a low T4/TBG ratio are referred to the pediatrician. In 2005, we showed that the Dutch NBS for CH is clinically and cost-effective with respect to detecting CH-T and CH-C [4]. In a recent evaluation of 11 years of the Dutch NBS for CH, we affirmed that T4 and the calculated T4/TBG ratio are very useful in detection of CH-C at the cost of a lower positive predictive value (PPV) compared to TSH-based screening programs [5].

Based on the premise that NBS for CH-C is useful and desirable, that false positives need to be prevented and that reliable assays for measurement of FT4 in DBS are currently not available in the Netherlands [6], optimization of the Dutch NBS for detection of CH-C is warranted to improve its specificity. Reference intervals (RIs) for diagnostic tests are crucial for the interpretation of the measurements. A RI is based on measurement of a laboratory test in a presumed healthy population and assessment of the 95% central range of all measurements. Neonatal RIs for DBS T4, TSH, and TBG concentrations and for the T4/TBG ratio as used in the Dutch NBS are currently not available. The aim of the present study was to establish these neonatal RIs and to investigate whether they could be used to reduce the number of false positives by improving the NBS algorithm, specifically for CH-C.

Methods

Sample Size and Subgroup Categories

According to the Clinical & Laboratory Standards Institute (CLSI) guidelines, a sample size of at least 120 reference subjects is required per category [7]. In order to establish RIs divided by sex (categories: males and females) and NBS sampling age after birth (categories: days 4, 5, 6, and 7), a population of at least 960 reference subjects is required for this study. RIs based on gestational age or weight would include premature neonates, but since this group is small compared to the group of full-term neonates, this category (defined as ≤36 weeks and ≤2,500 g) was not included in the current study.

Study Procedures

In the Netherlands, blood samples obtained by heel puncture are collected on filter paper between 72 and 168 h (days 4–7) after birth. For the current study, DBS T4, TSH, and TBG were measured prospectively during 18 subsequent days in all dried blood samples that were sent to the neonatal screening laboratory (part of the Endocrine Laboratory) in Amsterdam for daily NBS routine in a fixed period (February/March 2019).

Routine NBS

In the Dutch NBS algorithm for CH, all newborns with a T4 ≤−3 SD of the daily mean are immediately referred to the pediatrician, unless TBG is ≤40 nmol/L blood, indicating complete TBG deficiency. Newborns with a T4 ≤−0.8 SD and TSH ≥22 mIU/L blood or a TSH ≥8 mIU/L blood in a second screen are at risk for CH-T and are referred. TBG is measured in DBS when T4 concentrations are ≤−1.6 SD of the daily mean, and subsequently, a calculated T4/TBG ratio ≤17 requires a second heel puncture. If a second screen yields the same result, the newborn is considered at risk for CH-C and is referred to the pediatrician. For a detailed explanation of the NBS algorithm and the used referral criteria, we refer to our recent publication [5].

Laboratory Measurements

All measurements were performed with the same methods as used in the Dutch routine NBS. T4 and TSH were measured using
an immunoassay (GSP®, Perkin Elmer®, Waltham, MA, USA), and TBG was measured using an ELISA (Monobind Inc®, Lake Forrest, CA, USA). The total-assay variation (CV%) of the T4 immunoassay was 7.1% at the lower level (mean 21.5 nmol/L), 4.6% at the level of the medium control (mean 54.5 nmol/L), and 4.4% at the level of the high control (mean 92.2 nmol/L). The TSH immunoassay had a total-assay variation of 6.1% at the lower level (mean 16.3 mIU/L) and 5.1% at the higher level (mean 67.9 mIU/L), and the TBG ELISA 7.7% at the lower level (mean 76 nmol/L), 9.1% at the level of the medium control (mean 138 nmol/L), and 8.6% at the level of the high control (mean 234 nmol/L). All measurements were performed as duplicates.

### Data Collection

Permission for the use of leftover heel prick blood from the NBS for this research project was given by the Dutch Research Committee on Neonatal Screening at the National Institute for Public Health and the Environment (RIVM). Data on sex and

| Table 1. Calculated DBS 95% RIs for T4, TSH, TBG, and the T4/TBG ratio in identified subgroups |
|---------------------------------------------------------------|
| **T4, nmol/L** | **Subgroup** | female days 4–5 | male days 4–5 | female days 6–7 | male days 6–7 |
| **95% RIs** | lower | upper | lower | upper | lower | upper | lower | upper |
| 60 | 126 | 53 | 118 | 57 | 111 | 55 | 113 |
| 56–62 | 119–132 | 49–57 | 116–125 | 55–60 | 108–120 | 51–58 | 109–119 |
| **Characteristics** | Sample size | 409 | 433 | 382 | 446 |
| Lowest value | 52 | 44 | 50 | 41 |
| Highest value | 141 | 136 | 148 | 137 |
| Arithmetic mean | 88 | 85 | 84 | 82 |
| Median | 87 | 85 | 84 | 82 |
| SD | 16 | 16 | 14 | 15 |

| **TSH, mIU/L** | **Subgroup** | day 4 | days 5–7 |
| **95% RIs** | lower | upper | lower | upper |
| <3.4 | 1.23 | 0.1 |
| 0.3 | 7.6 |
| 1.5 | 1.2 |
| 1.3 | 1.1 |
| 1.0 | 0.7 |

| **TBG, nmol/L** | **Subgroup** | female | male | T4/TBG ratio |
| **95% RIs** | lower | upper | lower | upper | days 4–5 | days 6–7 |
| 125 | 274 | 113 | 270 | >21 | >20 |
| 118–128 | 264–285 | 109–116 | 263–277 | 20–21 | 19–20 |
| **Characteristics** | Sample size | 791 | 879 | 842 | 828 |
| Lowest value | 91 | 70 | 17 | 14 |
| Highest value | 359 | 351 | 53 | 48 |
| Arithmetic mean | 189 | 183 | 29 | 27 |
| Median | 185 | 180 | 28 | 27 |
| SD | 39 | 40 | 5 | 5 |

Measurements were performed in (full) blood. CI, confidence interval of the lower and the upper limit of the RI; RI, reference interval; SD, standard deviation; T4, thyroxine; TBG, thyroxine-binding globulin; TSH, thyroid-stimulating hormone; DBS, dried blood spot.
NBS sampling age were collected directly and anonymously from the heel puncture cards. NBS sampling age was defined in hours after birth and reported in days (NBS day 1 = 0–24 h after birth). The NBS Privacy Committee (at the Netherlands Organization for Applied Scientific Research [TNO], department of Child Health) gave permission to use available CH NBS data of referrals (2007–2017).

Statistical Analyses
IBM SPSS Statistics version 25 was used for descriptive statistics and comparisons. Outliers were detected by the D/R ratio, with a cutoff value (COV) of 1/3. To calculate the T4/TBG ratios in the reference population, we used the established formula \( \frac{(T4 \text{ in SD} + 5.1) \times 1,000}{TBG \text{ (nmol/L blood)}} \) [4]. The average and the spread were presented as mean and SD for normally distributed variables and as median and interquartile range (IQR) for non-normal distributions. To approach normality in heavily skewed distributions, a log-transformation was applied before proceeding. The effects of sex and NBS sampling age on NBS parameters T4, TSH, TBG, and the T4/TBG ratio were assessed by conducting a two-way ANOVA, allowing for unequal sample sizes of subgroups, followed by the Tukey post hoc test to compare the means of relevant subgroups. In MedCalc® version 18.5, 95% RIs for T4, TSH, and TBG, results with a high duplo variation \((n = 50)\) were excluded, thus leaving 1,670 cards for further analyses. Descriptive statistics of the measured T4, TSH, and TBG concentrations, and the calculated T4/TBG ratio in the reference population, as well as divided by sex and NBS sampling age are presented in online suppl. Table 1; see www.karger.com/doi/10.1159/000513516 for all online suppl. material.

T4
T4 was significantly higher in females compared to males. Also, a statistically significant difference between NBS sampling ages was found, leading to identification of two homogeneous subsets: (1) days 4 and 5, and (2) days 6 and 7. Calculated RIs for T4 were 60–126 (female...
days 4 and 5), 53–118 (male days 4 and 5), 57–111 (female days 6 and 7), and 55–113 (males days 6 and 7) nmol/L blood. The total sample RI was 56–118 nmol/L blood.

**Thyroid-Stimulating Hormone**

TSH was not different between females and males, but concentrations were significantly different between NBS sampling ages, forming two homogeneous subsets: (1) day 4 and (2) days 5, 6, and 7. The RIs for TSH were <3.4 and <2.4 mIU/L blood, respectively. The total sample 95% RI was <2.6 mIU/L blood.

**TBG**

TBG was significantly different between females and males, but concentrations were not significantly different between NBS sampling ages. The RIs were 125–274 (females) and 113–270 (males) nmol/L blood. The total sample 95% RI was 116–271 nmol/L blood.

**T4/TBG Ratio**

The T4/TBG ratio was not different between females and males, but a statistically significant difference was found between NBS sampling ages, leading to identification of two homogeneous subsets: (1) days 4 and 5, and (2) days 6 and 7. The RIs for the T4/TBG ratio were >21 and >20, respectively. The total sample RI was >20.

**Reference Population Compared to Historical NBS Referrals**

In 11 years (2007–2017) of NBS for CH, the T4 and T4/TBG ratio-based referral criteria led to referral of 83 CH-C patients and 1,984 false positives [5].

**T4 and T4/TBG Ratio Referrals versus Reference Population**

All detected CH-C patients were referred based on a T4 concentration ≤−3 SD or a T4/TBG ratio ≤17 (TBG is only measured when T4 is ≤−1.6 SD). The highest T4 concentration in CH-C patients was 60 nmol/L blood, overlapping with the lower end of the T4 RI. However, the T4/TBG ratio in these patients separated them from the healthy reference population (blue CH-C patients, shown in Fig. 1a). In all but one of the T4-based referrals, the T4/TBG ratio was below the RI and current COV. False-positive referrals due to T4 or T4/TBG ratio are displayed together with the healthy reference population in Figure 1b. A substantial number of T4/TBG ratio false-positive referrals showed a large overlap with T4 and T4/TBG ratio values of CH-C patients, but 10% (n = 118) of this group with a T4 SD value between −1.6 and −3.0 had a T4 >60 nmol/L blood.

All CH-C patients had a TBG concentration within or above the TBG RI, except for one patient with a TBG of 59 nmol/L blood, a T4 of 12 nmol/L blood (shown in Fig. 1c), and a T4/TBG ratio of 20.3. False-positive referrals due to a T4 ≤−3 SD (n = 788), however, showed a partial overlap with CH-C patients and had a variety of T4/TBG ratios. Figure 1d shows that 364 (46%) of this group false-positives referred because of a T4 ≤−3 SD, had TBG concentrations below the TBG RI, indicating possible partial TBG deficiency.

**Discussion**

With this study, we established neonatal RIs for DBS T4, TSH, and TBG concentrations, and the calculated T4/TBG ratio as used in the Dutch NBS for CH. We established RIs based on sex and NBS sampling age for each parameter.

Separate RIs for TSH could be considered for newborns screened on day 4 versus days 5, 6, and 7, as an age-based difference in TSH concentrations was observed. This difference can be explained by the TSH surge that occurs in newborns directly after birth due to thyrotropin-releasing hormone secretion induced by cold. Subsequently, the neonatal TSH surge causes an increase of the serum FT4 in the first days of life, peaking at day 3 [9], and probably is the reason for the slightly higher DBS T4 concentrations on days 4 and 5. The COV for DBS TSH in our NBS is ≥8 mIU/L, which makes a day specific RI irrelevant for daily practice. None of the subjects in the reference population had a TSH ≥8 mIU/L blood.

TBG concentrations were higher in females compared to males, resulting in higher total T4 concentrations in females, an effect that is likely to be mediated by estrogen [10]. Although statistically significant, the differences between subgroups were small for T4, TBG, and the T4/TBG ratio, and therefore, one RI for the whole reference population seems sufficient for these parameters [8]. Due to the nature of our CH NBS algorithm, TSH and TBG are currently only determined in the population with relatively low T4 values. This study provides previously lacking information on these parameters in a complete population of healthy newborns.

In our recent evaluation of the Dutch CH NBS, we observed that the majority of full-term false-positive referrals were due to the (separate) T4 and T4/TBG ratio referral criteria [5]. With the current study, we visualized the
Fig. 1. T4 concentrations versus T4/TBG ratios of CH-C patients (a) and FP (b), and T4 versus TBG concentrations in CH-C patients (c) and FP (d) in 11 years CH NBS, compared to the healthy reference population. 95% RIs for T4 (56–118 nmol/L blood) and TBG (116–271 nmol/L blood) are displayed as black lines. The current COV (≤17) for the T4/TBG ratio is displayed as a dashed line. Orange circles (a–d): the healthy reference population (n = 1,670). Blue diamonds (a, c): CH-C patients that were referred due to a T4/TBG ratio ≤17 (n = 54). Yellow diamonds (a, c): CH-C patients that were referred due to a T4 ≤−3 SD (n = 29). Gray circles (b, d): FP that was referred due to a T4/TBG ratio ≤17 (n = 1,196). Turquoise circles (b): FP that was referred due to a T4 ≤−3 SD (n = 788). Green and purple circles (d): same group as the turquoise referrals, but now divided by a TBG concentration within or above the RI (green, n = 424) or below the RI (purple, n = 364). CH-C, central congenital hypothyroidism; FP, false-positive; NBS, newborn screening; RI, reference interval; T4, thyroxine; TBG, thyroxine-binding globulin.
DBS T4 and TBG concentrations and the calculated T4/TBG ratio of CH-C patients and false-positive referrals, and compared these values to those of healthy newborns. CH-C patients can clearly be distinguished from the reference population based on their T4 concentration and T4/TBG ratio, confirming the usefulness of this approach. Although the large number of false-positive referrals (low specificity) forms the major drawback of the current NBS algorithm to detect also CH-C patients, it should be noted that between 1995 and 2015 per year on average 0.8 patients with CH-C were missed by NBS (unpublished data from a national voluntary registration for pediatric disorders). In addition, in a recent study, we showed that this number may be even higher (2–3 missed CH-C patients per year) [11]. Hence, the sensitivity of the Dutch screening algorithm to detect CH-C patients is not 100%. The large overlap between CH-C patients and false-positive referrals was confirmed (shown in Fig. 1), but overlap between these groups and the reference population barely existed as the reference population did not contain any false-positive referrals and obviously no patients. We postulate that false-positive referrals with a DBS T4 concentration in the lower end of the RI could be prevented by altering the limit at which the T4/TBG ratio is calculated. Currently, a TBG is measured when T4 is ≤−1.6 SD (T4 median 59, IQR 55–62 nmol/L blood). Expressing the DBS T4 concentration as a SD value has served for years as a means for harmonization of different radioactive T4 immunoassays between the regional Dutch laboratories. This, however, is not necessary anymore as the same T4 immunoassay is in use in all Dutch screening laboratories since 2003. Although two of the detected CH-C patients had a T4 of 60 nmol/L blood, our data show that no newborns with an absolute T4 concentration of >60 nmol/L blood had CH, suggesting that a T4 COV of ≤60 nmol/L blood might replace the currently used ≤−1.6 SD as the limit below which a TBG measurement is required, ultimately preventing 10% of T4/TBG ratio false-positive referrals.

Also, a large group false-positives were referred based on their T4 alone (T4 ≤−3 SD, TBG >40 nmol/L blood). Currently, TBG does not play a direct role in the referral process of these newborns (except if TBG <40 nmol/L blood). We, however, observed that in 46% (n = 364) of these false-positive referrals the TBG concentration was below the TBG RI (<116 nmol/L blood; shown in Fig. 1d), but >40 nmol/L, which is suggestive of the relatively common benign partial TBG deficiency (prevalence 1:4,000). A partial or complete TBG deficiency results in (relatively) low total T4 concentrations [12]. In contrast, only one CH-C patient with a TBG concentration below the RI was referred (shown in Fig. 1c) based on T4 ≤−3 SD (and exhibited a normal T4/TBG ratio of 20.3). This seems to be an exceptional case of combined CH-C and partial TBG deficiency. We, therefore, conclude that by taking partial TBG deficiency into account, approximately half of T4 false-positive referrals may be prevented at the cost of missing one CH-C patient (in 11 years of NBS). The remaining group of false-positive referrals unfortunately is very similar to CH-C (normal TBG and a low to subnormal T4), and its number cannot be reduced with currently available information from our evaluation study of the CH NBS algorithm and this neonatal RIs study.

In conclusion, this study provides newly established RIs for the NBS parameters T4, TSH, TBG, and T4/TBG ratio as used in the Dutch NBS. Separate RIs for sex and NBS sampling age are not of added value for the evaluated screening parameters DBS T4, TSH, and TBG concentrations, and the T4/TBG ratio. The main finding of our study is that by using the TBG RIs to recognize partial TBG deficiency, approximately half of the low T4 false-positive referrals (due to partial TBG deficiency) may be prevented. This suggested adaptation of the Dutch NBS for CH may lead to an improvement of the PPV while maintaining the current sensitivity for CH-C detection. Regular evaluation and further research for improvement of the algorithm are required to further improve the PPV.

Acknowledgements

The authors would like to thank the Dutch “Newborn screening working group for CH Optimization,” initiated by the National Institute of Public Health (RIVM), for its contribution to this project.

Statement of Ethics

This study has been approved with a signed statement by the NBS Privacy Committee of TNO. Parents participating in the neonatal screening program of the Netherlands give consent for both participation and anonymous use of leftover heel puncture blood for scientific research unless they actively declined.

Conflict of Interest Statement

Annet M. Bosch has received a speaker’s fee from Nutricia and has been a member of advisory boards for Biomin. All other authors have no conflicts of interest to declare.
Funding Sources

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Author Contributions

Kevin Stroek and Anita Boelen have made substantial contributions to the conception and design of the work, to the acquisition, analysis, and interpretation of data for the work and participated in drafting the work or revising it critically for important intellectual content. Annemieke C. Heijboer, Robert de Jonge, and A.S. Paul van Trotsenburg have made substantial contributions to the conception and design of the work and the interpretation of data for the work and participated in drafting the work or revising it critically for important intellectual content. Marja van Veen has made substantial contributions to the acquisition and analysis of data for the work and participated in revising the manuscript critically for important intellectual content. Catharina P.B. van der Ploeg, Annet M. Bosch, and Nitash Zwaveling-Soonawala have made substantial contributions to the interpretation of data for the work and participated in revising the manuscript critically for important intellectual content. All the authors approved the final version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1 LaFranchi SH. Newborn screening strategies for congenital hypothyroidism: an update. J Inherit Metab Dis. 2010;33(Suppl 2):S225–33.
2 Ford G, LaFranchi SH. Screening for congenital hypothyroidism: a worldwide view of strategies. Best Pract Res Clin Endocrinol Metab. 2014;28(2):175–87.
3 Kilberg MJ, Rasooly IR, LaFranchi SH, Bauer AJ, Hawkes CP. Newborn screening in the US may miss mild persistent hypothyroidism. J Pediatr. 2018;192:204–8.
4 Lanting CI, van Tijn DA, Loeber G, Vulsma T, de Vijlder JJ, Verkerk PH. Clinical effectiveness and cost-effectiveness of the use of the thyroxine/thyroid-binding globulin ratio to detect congenital hypothyroidism of thyroidal and central origin in a neonatal screening program. Pediatrics. 2005;116(1):168–73.
5 Stroek K, Heijboer AC, Bouva MJ, van der Ploeg CPB, Heijnen MA, Weijman G, et al. Critical evaluation of the newborn screening for congenital hypothyroidism in the Netherlands. Eur J Endocrinol. 2020;183(3):265–73.
6 Boelen A, van Veen M, Verkerk PH, Diепendaal G, Loeber G, Elvers B, et al. Measuring free thyroxine levels in neonatal heel-prick samples. Clin Chim Acta. 2013;423:51–5.
7 Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, et al. Clinical and laboratory standards institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline-third edition. CLSI document EP28-A3c (ISBN 1-56238-682-4). Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
8 Sinton TJ, Cowley DM, Bryant SJ. Reference intervals for calcium, phosphate, and alkaline phosphatase as derived on the basis of multi-channel-analyzer profiles. Clin Chem. 1986;32(1 Pt 1):76–9.
9 Fisher DA, Nelson J, Carlton EI, Wilcox R. Maturation of human hypothalamic-pituitary-thyroid function and control. Thyroid. 2000;10:229–34.
10 Ain K, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metabol. 1987;65:689–96.
11 van Jersel I, van Santen HM, Zandwijken GRJ, Zwaveling-Soonawala N, Hokken-Koelega ACS, van Trotsenburg ASP. Low FT4 concentrations around the start of recombinant human growth hormone treatment: Predictor of congenital structural hypothalamic-pituitary abnormalities? Horm Res Paediatr. 2018;89(2):98–107.
12 Pappa T, Ferrara AM, Refetoff S. Inherited defects of thyroxine-binding proteins. Best Pract Res Clin Endocrinol Metab. 2015;29(5):735–47.